Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab long-term extension in neovascular age-related macular degeneration
NL-OMON50774Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of faricimab in exudative macular degeneration (2 arms), sponsored by Roche. Primary endpoints: Incidence and severity of ocular adverse events and Incidence and severity of non-ocular adverse events. Started Dec 2021; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON50774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50774.